860478P
Avanti
cis-4-methylsphingosine
Avanti Research™ - A Croda Brand
Synonym(s):
5-Nonadecene-1,4-diol, 3-amino-5-methyl-, (3R,4S,5Z)-
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
form
powder
packaging
pkg of 1 × 5 mg (860478P-5mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand
lipid type
sphingolipids
shipped in
dry ice
storage temp.
−20°C
SMILES string
CCCCCCCCCCCCC/C=C(C)\[C@@H](O)[C@@H](N)CO
General description
cis-4-methylsphingosine (cis-4M-Sph) is a methyl-branched sphingosine analog.
Biochem/physiol Actions
cis-4-methylsphingosine (cis-4M-Sph) modulates sphingosine 1 phosphate (S1P) receptor through its metabolite cis-4-methylsphingosine-1-phosphate (cis-4M-S1P). This leads to S1P receptor internalization and desensitization. cis-4M-Sph shows an inhibitory effect on serine palmitoyltransferase activity.
Packaging
5 mL Amber Glass Screw Cap Vial (860478P-5mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Regulatory Information
新产品
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
The Journal of biological chemistry, 272(25), 15825-15833 (1997-06-20)
The effect of six different structurally modified sphingosine analogues on biosynthesis of sphingolipids was studied in primary cultured murine cerebellar neurons. Treatment of cells with cis-4-methylsphingosine at micromolar levels resulted in a markedly decreased sphingolipid biosynthesis, whereas the other compounds
Biochemical pharmacology, 81(5), 617-625 (2010-12-18)
Sphingosine-1-phosphate (S1P) acts as high affinity agonist at specific G-protein-coupled receptors, S1P(1-5), that play important roles e.g. in the cardiovascular and immune systems. A S1P receptor modulating drug, FTY720 (fingolimod), has been effective in phase III clinical trials for multiple
Molecular medicine reports, 16(5), 7039-7047 (2017-09-14)
Mesenchymal stem cell (MSC)‑based therapies have demonstrated efficacy in animal models of cardiovascular diseases. However, MSCs decrease in quantity and quality with age, which reduces their capacity for damage repair. Long noncoding (lnc) RNAs regulate gene transcription and the fate
International journal of molecular medicine, 42(2), 1054-1063 (2018-05-12)
Stroke is the second most common cause of death worldwide, and thus, it imposes great financial burdens on both individuals and society. Mesenchymal stem cell (MSC) therapy is a promising approach for ischemic brain injury. However, MSC treatment potential is
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service